Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease

Table 2

The quality of the nine studies.

Study year	Research method	Randomization	Blinding	Allocation concealment	Withdrawal and loss	Intention to treat analysis	Baseline demographic characteristics	Jadad score	Quality
Fishbane et al. [4], 2009	Prospective, randomized, placebo-controlled, double-blinded trial	Computer generated	Double-; blinded	Adequate	Description	Used	Similar	5	A
Alborzi et al.[5], 2008	A randomized, double-blinded pilot trial	Computer generated	Double-; blinded	Adequate	Description	Used	Similar	5	A
Agarwal et al.[6], 2005	Three, randomized, placebo-controlled, double-blinded trials	—	Double-; blinded	Unclear	—	Unclear	Similar	2	B
Martin et al.[7], 1998	Randomized, placebo-controlled, double-blinded multi-investigator study	—	Double-; blinded	Unclear	No	—	Similar	3	B
Abboud et al.[8], 2006	Three, prospective, randomized, placebo-controlled, double-blinded multicenter studies	—	Double-; blinded	Unclear	—	Unclear	Similar	2	B
Coyne et al.[9], 2006	Three, randomized, placebo-controlled trials	Computer generated	Double-; blinded	Adequate	—	Unclear	Similar	4	B
Greenbaum et al.[10], 2007	Randomized, placebo-controlled, double-blinded trial	—	Double-; blinded	Unclear	Description	Unclear	Similar	3	B
Ross et al.[11], 2007	Randomized, placebo-controlled, double-blinded trial	Computer generated	Double-; blinded	Adequate	—	Unclear	Similar	3	B
De Zeeuw et al. [12], 2010	A multicenter randomized placebo-controlled, double-blinded clinical trial	Computer generated	Double-; blinded	Adequate	Description	Used	Similar	5	A